An Open Label, Multicenter Phase II Clinical Study to Evaluate Efficacy , Safety and PK of HLX208 in Metastatic Colorectal Cancer (mCRC) With BRAF V600E Mutation
Latest Information Update: 10 Aug 2023
Price :
$35 *
At a glance
- Drugs RX 208 (Primary)
- Indications Colorectal cancer
- Focus Therapeutic Use
- Sponsors Shanghai Henlius Biotech
- 07 Aug 2023 Planned End Date changed from 28 Feb 2025 to 28 Jun 2025.
- 07 Aug 2023 Planned primary completion date changed from 30 Jul 2023 to 30 Jan 2024.
- 07 Aug 2023 Status changed from recruiting to active, no longer recruiting.